Navigation Links
NxStage® to Report Fourth Quarter and Full Year 2011 Financial Results
Date:1/20/2012

LAWRENCE, Mass., Jan. 20, 2012 /PRNewswire/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced plans to release its financial results for the fourth quarter and full year ended December 31, 2011 on Wednesday, February 29, 2012  before the opening of the financial markets.

(Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO )

NxStage will also host a conference call at 9:00 a.m. Eastern Time on Wednesday, February 29, 2012 to discuss its fourth quarter and year-end 2011 financial results. To listen to the conference call, please dial 877-392-9886 (domestic) or 707-287-9329 (international). The call will also be webcast LIVE and can be accessed via the investor relations section of the Company's website at www.nxstage.com.

A replay of the conference call will be available 2 hours after the completion of the call through March 14, 2012.  To access the replay dial 855-859-2056 (domestic) or 404-537-3406 (international) and reference conference ID 45478602.  An online archive of the conference call can be accessed via the investor relations section of the Company's website at www.nxstage.com.

About NxStage

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. For more information on NxStage and its products, please visit the company's website at www.nxstage.com.


'/>"/>

SOURCE NxStage Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. NxStage® Ranked Number 141 on the Fastest Growing Company in North America on Deloittes 2011 Technology Fast 500™
2. NxStage® to Report Third Quarter Fiscal 2011 Financial Results
3. NxStage® Highlights Non-Medical Emergency Preparedness Guidebook for System One™ Home Hemodialysis Patients
4. NxStage® Enters Into New Lease for Corporate Headquarters Within Lawrence, MA
5. NxStage® Supports Initiative by Patient Advocacy Groups to Educate Policymakers about the Benefits of Frequent Home Hemodialysis
6. NxStage® Advances Global Growth Strategy with System One™ Regulatory Approval and Distribution Agreement in Australia and New Zealand
7. Chronic Disease Research Group Study Shows Daily Home Hemodialysis Therapy with the NxStage® System One™ is Associated with Lower Risk of Mortality and Higher Survival Estimates Compared to Conventional Thrice-Weekly Dialysis
8. NxStage® Names Michael Miller, Jr. President, International
9. NxStage® to Report First Quarter Fiscal 2011 Financial Results
10. New NxStage® FREEDOM Data Shows Continued, Marked Benefits for Patients Using the System One™ for Daily Home Hemodialysis Throughout a 12 Month Period
11. In Celebration of the 31st Annual Dialysis Conference, NxStage® Announces Over 5,000 Patients Using the System One™ for Home Hemodialysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2012)... Vanda Pharmaceuticals Inc. (NASDAQ: VNDA ), ... commercialization of products for central nervous system disorders, ... at the Society for Research on Biological Rhythms ... The first poster entitled Pleiomorphic Expression of ... insight into the challenges faced by individuals suffering ...
(Date:5/22/2012)... ALLEGAN, Mich., May 22, 2012  Perrigo Company ... final approval from the U.S. Food and Drug ... for butoconazole nitrate 2% vaginal cream, the generic ... submit a substantially complete ANDA with a paragraph ... marketing exclusivity. Perrigo is working exclusively with KV Pharmaceutical ...
(Date:5/22/2012)... Generics, a division of Prodigy Health Supplier Corporation ... generic equivalent of the branded drug Camptosar by ... Laboratories to develop a portfolio of oncology products. ... developed through the partnership that will add consistent ... market, which has experienced record levels of shortages ...
Breaking Medicine Technology:Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting 2Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting 3Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream 2Perrigo Receives FDA Approval for Butoconazole Nitrate 2% Vaginal Cream 3GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 1GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 2GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 3GeoVax Initiates Third Site For Therapeutic Testing of Its HIV Vaccine 19815 4ULURU Inc Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor 18324 1ULURU Inc Announces the Engagement of Gilford Securities Incorporated to Serve as the Companys Financial Advisor 18324 2MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 1MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 2MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 3MAP Pharmaceuticals to Present Data on LEVADEX AE at the 15th Congress of the International Headache Society 18320 4
... Planning for Phase 3 Trial Initiation on Track ... Limited (ASX: PGL; Nasdaq: PGLA) today announced it ... Contract Research,Organisation, to utilise their services for a ... the execution of the,Phase 3 clinical trial of ...
... Topic of Drug Repurposing and ... Indian Clinical Trial Strategy, ... biopharmaceutical company, announced today,that Chief Executive Officer, John Maki, and ... 234th American Chemical,Society National Meeting on Sunday, August 19, 2007. ...
Other Medicine Technology:Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88 2Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88 3Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA 2Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA 3
(Date:5/23/2012)... second edition of Law and the American Health Care ... 2012. Building on its 1997 predecessor, the second edition ... intersection of law and the U.S. health care system. ... a time of unprecedented change in how health care ... of study, the book focuses on how a dramatically ...
(Date:5/23/2012)... of the same kind, thereby triggering skeletal and cardiac ... from the RUB Heart and Diabetes Center NRW in ... an interdisciplinary research project with colleagues from the universities ... Journal of Biological Chemistry . , One ... stabilizing filaments inside of the cells. Different mutations in ...
(Date:5/23/2012)... FRANCISCO The number of viral infections during infancy ... to a new study from researchers in the Netherlands. ... later in childhood, this association was due in part ... in infancy, particularly rhinovirus, are thought to be a ... unclear whether this association is due to the viruses ...
(Date:5/23/2012)... present findings on prostate cancer risk, screening, treatment ... of the American Urological Association May 19-23 in ... to provide expert comment for reporters covering the ... presented and their embargo dates include: , ... surgery hormone therapy , Embargoed until 10:30 a.m. ...
(Date:5/22/2012)... MAYWOOD, Ill. -- Children born with cleft lip, ... medical challenges beyond appearance. , Patients can face ... well as social and psychological challenges, Laura Swibel ... colleagues write in the June 2012 issue of ... "The management of patients with craniofacial syndromes is ...
Breaking Medicine News(10 mins):Health News:Landmark textbook on health care and the US legal system released 2Health News:Aggregating instead of stabilizing: New insights into the mechanisms of heart disease 2Health News:Viral infections in infancy are not associated with wheezing symptoms in later childhood 2Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 2Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 3Health News:Mayo Clinic urologists present findings at American Urological Association Annual Meeting 4Health News:Cleft lip/palate cause much more than cosmetic problems 2
... 5 year old boy in Thailand which has raised the toll ... in direct contact with chickens, but the officials feel// that he ... ,The latest good news to ease bird flu fear has come ... has given permission to manufacturers to produce generic version of Tamiflu, ...
... for some overweight people—they cannot reduce weight by exercise ... obese patients often prescribe exercise as part of a ... led by psychologist Rona Levy at the University of ... may be hampered by a variety of gastrointestinal problems ...
... cancer should not be a stimulation to be relieved ... infection//. ,This arises due to its treatment ... with the general population. ,According to the study ... colorectal cancer, lung cancer, renal cancer, thyroid cancer, soft ...
... professor of neurology at the University of California who ... stroke has highlighted that more than// 32,000 neurons (brain ... episode of stroke. In addition, nearly 14 billion synapses ... 7.5 miles are lost in just a single minute ...
... The increasing number of people resorting to sleeping pills for ... more effective medications. However, they may not have the best ... ,The importance of sleep can be inferred form ... man healthy, wealthy and wise’. For those of them who ...
... The chances of the babies falling a victim to cot ... a study which the British Medical Journal published. The babies ... smoke are particularly at risk where the Sudden Infant Death ... over 300 babies die due to SIDS every year. There ...
Other Medicine News:Health News:Stroke Destroys Nearly 32, 000 Neurons In Just A Second! 2Health News:Newer Generation Sleeping Pills Lack Superior Performance 2
... the revolutionary OxiMax® Pulse Oximetry System, ... Nellcor's best-in-class pulse oximetry with the ... OxiMax N-595 Pulse Oximeter is equipped ... technology, which enables it to withstand ...
The Model 340 is intended for continuous pulse oximetry and has visual and audible alarms to aid with patient monitoring....
A pocket-sized pulse oximeter. Perfect for the physician's office, emergency medicine, hospitals and clinics, and home health care....
... The Autocorr Pulse Oximeter with SAC ... unique patented software to extract SpO 2 ... in a new way. This cost-effective ... study functions as standard features, and a ...
Medicine Products: